论文部分内容阅读
血小板聚集形成血栓是急性冠状动脉综合征和经皮冠状动脉介入（ PCI）治疗术后发生不良心血管事件的基本原因，抗血小板治疗是防治冠状动脉粥样硬化性心脏病（冠心病）的基石。然而，同一种抗血小板药物在不同个体可产生不同的抗血小板效应，抗血小板药物低反应者血栓事件可能增加，而抗血小板药物高反应者出血风险加大。因此，通过检测血小板功能以预测患者不良心血管事件的风险及评估出血风险有着重要的临床意义。“,”Platelet aggregation plays a pivotal role in acute coronary syndrome ( ACS) and adverse cardi-ovascular events after percutaneous coronary intervention ( PCI) therapy.Antiplatelet therapy is the corner-stone of prevention and treatment of coronary arterial disease.However,an antiplatelet agent may produce dif-ferent effects in different individuals:high on-treatment platelet reactivity may lead to the occurrence of bleeding,low on-treatment platelet reactivity can increase the risk of thrombotic events.Therefore,detecting platelet function to predict the risk of adverse cardiovascular events has great clinical significance .